Showing results (501-510 of 534) with videos related to
Sort By:
Pageof 54
Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Systematic adjudication of myocardial infarction end-points in an international clinical trialKenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, et al.Current Controlled Trials in Cardiovascular Medicine|January 25, 2002
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyKenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, et al.The American Journal of Cardiology|April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.Nature Genetics|March 31, 2004
Assessing the impact of population stratification on genetic association studiesMatthew L Freedman, David Reich, Kathryn L Penney, et al.American Journal of Human Genetics|September 12, 2007
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarctionGong-Qing Shen, Lin Li, Domenico Girelli, et al.American Journal of Human Genetics|September 22, 2005
Identification of four gene variants associated with myocardial infarctionDov Shiffman, Stephen G Ellis, Charles M Rowland, et al.Nature Medicine|March 13, 2026
A clinical environment simulator for dynamic AI evaluationLuyang Luo, Sung Eun Kim, Xiaoman Zhang, et al.American Heart Journal|June 23, 2007
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR studyDeepak L Bhatt, Derek P Chew, Cindy Grines, et al.JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.Pageof 54